Warning: The NCBI web site requires JavaScript to function. more...
A retrospective analysis of the change in anti-malarial treatment policy: Peru.
Williams HA, Vincent-Mark A, Herrera Y, Chang OJ.
Malar J. 2009 Apr 28;8:85. Review.
Related citations
Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug.
Mubyazi GM, Gonzalez-Block MA.
Malar J. 2005 Oct 20;4:51.
The process of changing national malaria treatment policy: lessons from country-level studies.
Williams HA, Durrheim D, Shretta R.
Health Policy Plan. 2004 Nov;19(6):356-70. Review.
The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya.
Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, Snow RW.
Malar J. 2007 May 29;6:72.
Modifying national malaria treatment policies in Peru.
Ruebush TK 2nd, Neyra D, Cabezas C.
J Public Health Policy. 2004;25(3-4):328-45.
The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania.
Mulligan JA, Mandike R, Palmer N, Williams H, Abdulla S, Bloland P, Mills A.
Trop Med Int Health. 2006 Apr;11(4):452-61.
Anti-malarial market and policy surveys in sub-Saharan Africa.
Diap G, Amuasi J, Boakye I, Sevcsik AM, Pecoul B.
Malar J. 2010 Apr 23;9 Suppl 1:S1.
The role of private drug vendors as malaria treatment providers in selected malaria endemic areas of Sri Lanka.
Rajakaruna RS, Weerasinghe M, Alifrangis M, Amerasinghe PH, Konradsen F.
J Vector Borne Dis. 2006 Jun;43(2):58-65.
Using evidence to change antimalarial drug policy in Kenya.
Shretta R, Omumbo J, Rapuoda B, Snow RW.
Trop Med Int Health. 2000 Nov;5(11):755-64.
Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.
Pongtavornpinyo W, Yeung S, Hastings IM, Dondorp AM, Day NP, White NJ.
Malar J. 2008 Nov 2;7:229.
[Molecular markers for malaria drug resistance: necessary but not sufficient criteria to decide change in treatment policy].
Mbacham W, Njikam N.
Med Trop (Mars). 2007 Apr;67(2):183-7. Review. French.
From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia.
Sipilanyambe N, Simon JL, Chanda P, Olumese P, Snow RW, Hamer DH.
Malar J. 2008 Jan 29;7:25.
Malaria-treatment policies: when and how should they be changed?
Fèvre EM, Barnish G.
Ann Trop Med Parasitol. 1999 Sep;93(6):549-60. Review.
Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!
Mutabingwa TK.
Acta Trop. 2005 Sep;95(3):305-15. Review.
[Knowledge and practice among health workers from the Thiès region with regard to new malaria treatment policies].
Souares A, Lalou R, Sene I, Sow D, Le Hesran JY.
Sante Publique. 2006 Jun;18(2):299-310. French.
Peru's population in the 1980s.
Sanders TG.
UFSI Rep. 1984 Dec;(27):1-9.
From evidence to action? Challenges to policy change and programme delivery for malaria in pregnancy.
Crawley J, Hill J, Yartey J, Robalo M, Serufilira A, Ba-Nguz A, Roman E, Palmer A, Asamoa K, Steketee R.
Lancet Infect Dis. 2007 Feb;7(2):145-55. Review.
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Primary Care Research Team Assessment (PCRTA): development and evaluation.
Carter YH, Shaw S, Macfarlane F.
Occas Pap R Coll Gen Pract. 2002 Feb;(81):iii-vi, 1-72.
[Current malaria situation in the Republic of Kazakhstan].
Bismil'din FB, Shapieva ZhZh, Anpilova EN.
Med Parazitol (Mosk). 2001 Jan-Mar;(1):24-33. Russian.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on